Seraphina Therapeutics Announces C15:0 Reverses Key Aspects of Cellular Fragility Syndrome in a Second Model
A new independent study has revalidated the use of C15:0 to reverse core components of a newly discovered nutritional C15:0 deficiency syndrome, called Cellular Fragility Syndrome, which may be impacting as many as 1 in 3 people globally.